Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Bache, Matthias ^a   Kappler, Matthias ^a   Wichmann, Henri ^a   Rot, Swetlana ^a   Hahnel, Antje ^a   Greither, Thomas ^a   Said, Harun M ^b   Kotzsch, Matthias ^c   Würl, Peter ^d   Taubert, Helge ^a   Vordermark, Dirk ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d Malteser St Franziskus Hospital gGmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPONTIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSARCOMA; HUMAN; HUMAN TISSUE; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; NEUROFIBROSARCOMA; OVERALL SURVIVAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; RISK FACTOR; SOFT TISSUE SARCOMA; TUMOR VOLUME; BLOOD; CELL HYPOXIA; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SARCOMA; SOFT TISSUE TUMOR; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CELL HYPOXIA; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OSTEOPONTIN; SARCOMA; SOFT TISSUE NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77952307612     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-132     Document Type: Article

References (37)

1. Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 2001, 1:621-632. 10.2174/1566524013363339, 11899236.
2. Bache M, Kappler M, Said HM, Staab A, Vordermark D. Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies. Curr Med Chem 2008, 15:322-338. 10.2174/092986708783497391, 18288988.
3. Vordermark D, Said HM, Katzer A, Kuhnt T, Hänsgen G, Dunst J, Flentje M, Bache M. Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer 2006, 6:207. 10.1186/1471-2407-6-207, 1564036, 16911785.
4. Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 2008, 27:103-118. 10.1007/s10555-007-9104-9, 18049863.
5. Tuck AB, O'Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N, Saad Z, Doig GS, Chambers AF. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 1998, 79:502-508. 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3, 9761120.
6. Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002, 62:3417-3427.
7. Boldrini L, Donati V, Dell'Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, Fontanini G. Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer 2005, 93:453-457. 10.1038/sj.bjc.6602715, 2361587, 16091764.
8. Sakaguchi H, Fujimoto J, Hong BL, Tamaya T. Clinical implications of osteopontin in metastatic lesions of uterine cervical cancers. Cancer Let 2007, 247:98-102.
9. Cho H, Hong SW, Oh YJ, Kim MA, Kang ES, Lee JM, Kim SW, Kim SH, Kim JH, Kim YT, Lee K. Clinical significance of osteopontin expression in cervical cancer. J Cancer Res Clin Oncol 2008, 134:909-917. 10.1007/s00432-007-0351-5, 18210151.
10. Forootan SS, Foster CS, Aachi VR, Adamson J, Smith PH, Lin K, Ke Y. Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer 2006, 118:2255-2261. 10.1002/ijc.21619, 16331611.
11. Bache M, Reddemann R, Said HM, Holzhausen HJ, Taubert H, Becker A, Kuhnt T, Hänsgen G, Dunst J, Vordermark D. Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels. Int J Radiat Oncol Biol Phys 2006, 66:1481-1487.
12. Celetti A, Testa D, Staibano S, Merolla F, Guarino V, Castellone MD, Iovine R, Mansueto G, Somma P, De Rosa G, Galli V, Melillo RM, Santoro M. Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness. Clin Cancer Res 2005, 11:8019-8027. 10.1158/1078-0432.CCR-05-0641, 16299231.
13. Chien CY, Su CY, Chuang HC, Fang FM, Huang HY, Chen CM, Chen CH, Huang CC. Clinical significance of osteopontin expression in T1 and T2 tongue cancers. Head Neck 2008, 30:776-781. 10.1002/hed.20783, 18228527.
14. Schneider S, Yochim J, Brabender J, Uchida K, Danenberg KD, Metzger R, Schneider PM, Salonga D, Hölscher AH, Danenberg PV. Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin Cancer Res 2004, 10:1588-1596. 10.1158/1078-0432.CCR-0565-3, 15014008.
15. Kolb A, Kleeff J, Guweidhi A, Esposito I, Giese NA, Adwan H, Giese T, Büchler MW, Berger MR, Friess H. Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. Cancer Biol Ther 2005, 4:740-746.
16. Higashiyama M, Ito T, Tanaka E, Shimada Y. Prognostic significance of osteopontin expression in human gastric carcinoma. Ann Surg Oncol 2007, 14:3419-3427. 10.1245/s10434-007-9564-8, 17896150.
17. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, Weber GF. Osteopontin-c is a selective marker of breast cancer. Int J Cancer 2008, 122:889-897. 10.1002/ijc.23204, 17960616.
18. Patani N, Jouhra F, Jiang W, Mokbel K. Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anticancer Res 2008, 28(6B):4105-4110.
19. Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 2001, 1552:61-85.
20. Jain S, Chakraborty G, Bulbule A, Kaur R, Kundu GC. Osteopontin: an emerging therapeutic target for anticancer therapy. Expert Opin Ther Targets 2007, 11:81-90. 10.1517/14728222.11.1.81, 17150036.
21. Gaumann A, Petrow P, Mentzel T, Mayer E, Dahm M, Otto M, Kirkpatrick CJ, Kriegsmann J. Osteopontin expression in primary sarcomas of the pulmonary artery. Virchows Arch 2001, 439:668-674.
22. Bramwell VH, Tuck AB, Wilson SM, Stitt LW, Cherian AK, Rorke SC, Al-Katib W, Postenka CO, Chambers AF. Expression of osteopontin and HGF/met in adult soft tissue tumors. Cancer Biol Ther 2005, 4:1336-1341.
23. Sulzbacher I, Birner P, Trieb K, Lang S, Chott A. Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors. Virchows Arch 2002, 441:345-349. 10.1007/s00428-002-0671-4, 12404059.
24. Würl P, Fittkau M, Meye A, Bartel F, Schmidt H, Schönfelder M, Taubert H. Low detection rate of p53 antibodies in sera of soft tissue sarcoma patients. Cancer Lett 2001, 170:199-205. 10.1016/S0304-3835(01)00604-8, 11463499.
25. Würl P, Kappler M, Meye A, Bartel F, Köhler T, Lautenschläger C, Bache M, Schmidt H, Taubert H. Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma. Lancet 2002, 359:943-945. 10.1016/S0140-6736(02)07990-4, 11918915.
26. Taubert H, Würl P, Greither T, Kappler M, Bache M, Bartel F, Kehlen A, Lautenschläger C, Harris LC, Kaushal D, Füssel S, Meye A, Böhnke A, Schmidt H, Holzhausen HJ, Hauptmann S. Stem cell-associated genes are extremely poor prognostic factors for soft-tissue sarcoma patients. Oncogene 2007, 26:7170-7174. 10.1038/sj.onc.1210530, 17525744.
27. van Unnik JA, Coindre JM, Contesso C, Albus-Lutter CE, Schiodt T, Sylvester R, Thomas D, Bramwell V, Mouridsen HT. Grading of Soft Tissue Sarcomas: Experience of the EORTC Soft and Bone Sarcoma Group. Eur J Cancer 1993, 29:2089-2093.
28. Kappler M, Kotzsch M, Bartel F, Füssel S, Lautenschläger C, Schmidt U, Würl P, Bache M, Schmidt H, Taubert H, Meye A. Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. Clin Cancer Res 2003, 9:1098-1104.
29. Zohar R, Suzuki N, Suzuki K, Arora P, Glogauer M, McCulloch CA, Sodek J. Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J Cell Physiol 2000, 184:118-30. 10.1002/(SICI)1097-4652(200007)184:1<118::AID-JCP13>3.0.CO;2-Y, 10825241.
30. Junaid A, Moon MC, Harding GE, Zahradka P. Osteopontin localizes to the nucleus of 293 cells and associates with polo-like kinase-1. Am J Physiol Cell Physiol 2007, 292:C919-26. 10.1152/ajpcell.00477.2006, 17005603.
31. Nordsmark M, Eriksen JG, Gebski V, Alsner J, Horsman MR, Overgaard J. Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol 2007, 83:389-397. 10.1016/j.radonc.2007.04.021, 17499868.
32. Luo X, Chen J, Song WX, Tang N, Luo J, Deng ZL, Sharff KA, He G, Bi Y, He BC, Bennett E, Huang J, Kang Q, Jiang W, Su Y, Zhu GH, Yin H, He Y, Wang Y, Souris JS, Chen L, Zuo GW, Montag AG, Reid RR, Haydon RC, Luu HH, He TC. Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Lab Invest 2008, 88:1264-1277. 10.1038/labinvest.2008.98, 18838962.
33. Liu SJ, Zhang DQ, Sui XM, Zhang L, Cai ZW, Sun LQ, Liu YJ, Xue Y, Hu GF. The inhibition of in vivo tumorigenesis of osteosarcoma (OS)-732 cells by antisense human osteopontin RNA. Cell Mol Biol Lett 2008, 13:11-19. 10.2478/s11658-007-0031-0, 17952379.
34. Dalla-Torre CA, Yoshimoto M, Lee CH, Joshua AM, de Toledo SR, Petrilli AS, Andrade JA, Chilton-MacNeill S, Zielenska M, Squire JA. Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma. BMC Cancer 2006, 6:237. 10.1186/1471-2407-6-237, 1609181, 17022822.
35. Saitoh Y, Kuratsu J, Takeshima H, Yamamoto S, Ushio Y. Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab Invest 1995, 72:55-63.
36. He B, Mirza M, Weber GF. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 2006, 25:2192-2202. 10.1038/sj.onc.1209248, 16288209.
37. Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 2007, 26:6361-6371. 10.1038/sj.onc.1210463, 17452979.